Login to Your Account


Treos Bio Ltd., a London-based company developing precision peptide cancer vaccines coupled with companion diagnostics, has enlisted Pharmaceutical Product Development LLC to manage a phase I trial of PolyPEPI-1018, its lead vaccine for colorectal cancer. Once an investigational new drug application the company is filing is accepted, the trial is expected to start by late January 2018.

HONG KONG – Research in T-cell therapy has been gaining momentum, with biotech giants like Gilead Sciences Inc. keenly investing in the area. Meanwhile, Lion TCR Pte. Ltd., a smaller company based in Singapore, is also seeing progress with its T-cell therapy treatment for hepatocellular carcinoma.

Nanology LLC's strategy is "almost like having a new molecular entity, in terms of the broadness of the [IP] around it, but on a more streamlined path to potential approval" if safety and efficacy pan out, Marc Iacobucci noted. 

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: